Home / Business and Economy / Diet Drugs Hit Restaurant Stocks Hard
Diet Drugs Hit Restaurant Stocks Hard
15 Mar
Summary
- Restaurant stocks are declining due to inflation and weight-loss drugs.
- GLP-1 drugs show an 8% spending decline in away-from-home food.
- A weaker job market also contributes to decreased restaurant demand.

The restaurant industry is experiencing a challenging year in 2026, with stocks reflecting broader economic pressures and evolving consumer behaviors. The S&P 500 Hotels, Restaurants and Leisure index has seen a 4% decline, outpaced by the broader S&P 500's 1.8% decrease. Major players like DoorDash, Chipotle, and Wendy's have experienced significant stock depreciation year-to-date. Conversely, Darden Restaurants, McDonald's, and Cava have demonstrated positive growth, indicating market volatility.
Two significant trends are impacting the sector: the increasing use of GLP-1 weight-loss drugs and a weakening job market. Research suggests households using GLP-1s reduced food-away-from-home spending by 8%, a habit that persists. While current adoption hasn't drastically affected chains, wider accessibility could disproportionately impact quick-service and fast-casual restaurants. Simultaneously, a downturn in the labor market, with job payrolls declining for several months in late 2025 and early 2026, correlates with weakened restaurant demand, especially affecting younger consumers who frequent fast-casual establishments.




